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Abstract: Genomic instability could be a beneficial predictor for anthracycline or taxane chemotherapy.
We interrogated 188 DNA repair genes in the METABRIC cohort (n = 1980) to identify genes that
influence overall survival (OS). We then evaluated the clinicopathological significance of ERCC1 in
early stage breast cancer (BC) (mRNA expression (n = 4640) and protein level, n = 1650 (test set), and
n = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (n = 2340) and
validation (TOP clinical trial cohort, n = 120); and protein level (n = 120)). In the multivariate model,
ERCC1 was independently associated with OS in the METABRIC cohort. In ER+ tumours, low ERCC1
transcript or protein level was associated with increased distant relapse risk (DRR). In ER−tumours,
low ERCC1 transcript or protein level was linked to decreased DRR, especially in patients who
received anthracycline chemotherapy. In LABC patients who received neoadjuvant anthracycline, low
ERCC1 transcript was associated with higher pCR (pathological complete response) and decreased
DRR. However, in patients with ER−tumours who received additional neoadjuvant taxane, high
ERCC1 transcript was associated with a higher pCR and decreased DRR. High ERCC1 transcript was
also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane. ERCC1
based stratification is an attractive strategy for breast cancers.
Keywords: ERCC1; anthracycline resistance; taxane sensitivity
1. Introduction
Anthracycline and taxane based adjuvant and neoadjuvant chemotherapies are standard
approaches in the management of early stage or locally advanced breast cancers to reduce distant
recurrence and improve survival [1–3]. Moreover, the recent development of multi-parameter
gene-expression assays, largely based on proliferation biomarkers, has facilitated the selection of
patients who are most likely to benefit from systemic chemotherapy [4]. However, despite the genomic
based selection, not all patients benefit from chemotherapy. In addition, chemotherapy related toxicity
(such as anthracycline induced cardiotoxicity/leukaemia and taxol induced irreversible peripheral
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neuropathy) can adversely impact overall outcomes. Therefore, the development of anthracycline
and/or taxane specific predictive biomarkers is desirable.
Chromosomal instability (CIN) that alters chromosome number or structure is a hallmark of cancer
including breast tumours [5–7]. Whilst genomic instability is a key driver of CIN, dysfunctional mitotic
mechanisms, such as defective spindle assembly checkpoints and defective sister chromatid cohesions
can also promote chromosomal instability [5–7]. Tumours with impaired DNA repair capacity and
CIN are sensitive to DNA damaging chemotherapeutics. In early breast cancer patients, duplication of
chromosome 17 centromere enumeration probe (Ch17CEP), a CIN marker, was previously shown to
be a strong predictor of benefit from anthracycline adjuvant chemotherapy in a prospective clinical
trial [8]. On the other hand, in a meta-analyses by the early breast cancer trialists collaborative group
(EBCTCG), benefit from taxanes (paclitaxel, docetaxel) based chemotherapy was most evident in
chromosomally stable low grade breast cancers [9,10]. In addition, CIN has been shown previously to
predict paclitaxel resistance in ovarian cancer patients [11].
Chemotherapy induced or radiotherapy induced DNA damage is processed by various DNA repair
pathways in cells. Emerging data provides strong evidence that overexpression of DNA repair factors
can also contribute to therapeutic resistance in cancers [12]. DNA adducts induced by chemotherapy
(such as by platinum and cyclophosphamide) are processed through the nucleotide excision repair
(NER) pathway. NER is a highly conserved, versatile and robust. NER is a complex pathway requiring
several proteins and their interacting partners. Although complex, two sub-pathways of NER have
been described: The transcription-coupled nucleotide excision repair (TC-NER) pathway, that targets
lesions specifically in the transcribed strand of expressed genes, and the global genome nucleotide
excision repair (GG-NER) pathway, that deals with lesions in the rest of the genome. Although
these NER sub-pathways are complex, basic steps in GG-NER include DNA damage recognition (by
XPC-HR23B complex), lesion demarcation and verification by TFIIH complex (Cdk7, Cyclin H, MAT1,
XPB, XPD, p34, p44, p52 and p62), assembly of a pre-incision complex (RPA, XPA and XPG), DNA
opening by XPB and XPD helicases, dual incision (by ERCC1–XPF and XPG endonucleases), release of
the excised oligomer and finally repair synthesis to fill in the resulting gap (RPA, RFC, PCNA, Pol
δ/ε, and ligation by ligase I) [13,14]. In TC-NER, translocating RNA polymerase II detects lesions in
the template. A role for ERCC8 (CSA) and ERCC6 (CSB) has also been suggested in DNA damage
recognition in TC-NER. Subsequent steps in TC-NER are similar to GC-NER.
ERCC1 protein is a critical player in NER. ERCC1 is non-catalytic but associates with XPF
endonuclease (also known as ERCC4) to form the ERCC1–XPF heterodimer. The ERCC1–XPF
heterodimer cleaves and facilitates the removal of bulky lesions, such as those induced by platinum
chemotherapy [15,16]. In addition the ERCC1–XPF heterodimer also has essential roles in other DNA
repair pathways, such as DNA recombinational repair and inter-strand crosslink repair [17,18]. ERCC1
and XPF siRNA depletion was previously shown to increase cisplatin sensitivity in non-small lung [19]
and breast cancer cells [20]. In a mouse xenograph model, ERCC1-deficient melanoma cells were also
observed to be 10-fold more sensitive to cisplatin than ERCC1-proficient cells [21]. ERCC1 as a marker
of chemotherapy resistance has been well described in other solid tumours, including lung, colorectal,
head, neck, gastric, bladder and ovarian cancers [22–26]. Given the critical role of ERCC1 in genomic
integrity, in the current study, we evaluated the role of ERCC1 as a biomarker in breast cancers.
2. Results
2.1. ERCC1 Transcript Is a Predictor of Tumour Grade and Chromosomal Instability in Early Stage breast
cancers (BCs)
A large body of clinical evidence confirms that high grade BCs is associated with chromosomal
instability. Given the critical role of ERCC1 in NER, DSB repair, ICL repair and chromosomal stability,
we evaluated ERCC1 transcripts in the METABRIC Cohort. A low level of ERCC1 transcript was
significantly associated with higher grade cancer, whereas low grade tumours were common in
high ERCC1 tumours (Table 1) (p values < 0.0001). Low ERCC1 transcript was also associated with
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Ki67 positivity, ER−, PAM50 Luminal B, Pam50 Her2, Pam50 basal and Genufu ER+/HER− (high
proliferation) tumours. On the other hand, low grade, Ki67 negative, PAM50 Luminal A and Genufu
ER+/HER− (low proliferation) were more common in tumours with high ERCC1 transcript (all
p values < 0.0001). To evaluate associations with chromosomal stability we investigated ERCC1 in
various integrative molecular cluster (intClust) phenotypes described in the METABRIC cohort. Low
ERCC1 transcript was linked to genomically unstable intClust.10 phenotype whereas high ERCC1 was
associated with chromosomally stable intClust.3, 4, 7 and 8 tumours. Together, the data provides the
first clinical evidence that low ERCC1 is a marker of chromosomal instability and aggressive phenotype
in BCs.
Table 1. Clinicopathological significance of ERCC1 mRNA expression in breast cancers.




≤1cm 43 (4.5%) 43 (4.4%)
0.481 5.2910
>1–2cm 247 (25.7%) 279 (28.8%)
>2–4cm 620 (64.5%) 601 (62.0%)
>4cm 51 (5.3%) 46 (4.7%)
Tumour Grade
1 35 (3.7%) 130 (14.1%)
4.4 × 10−37 <0.000012 305 (32.0%) 460 (49.8%)
3 612 (64.3%) 334 (36.1%)
Lymph Node Group
Negative 486 (49.8%) 528 (54.2%)
0.051 0.0623Positive 490 (50.2%) 446 (45.8%)
Histological Types
IDC-NST 837 (85.8%) 704 (72.3%)
1.33 × 10−15 <0.00001Medullary Carcinoma 20 (2.0%) 12 (1.2%)Invasive special type 104 (10.7%) 247 (25.4%)
Invasive others 15 (1.5%) 11 (1.1%)
Ki67 Expression
Negative 375 (38.4%) 600 (61.6%)
1.37 × 10−24 <0.00001Positive 601 (61.6%) 374 (38.4%)
P53 Mutation
Wild type 325 (82.9%) 383 (92.3%)
4.9 × 10−5 <0.00001Mutant 67 (17.1%) 32 (7.7%)
ER Expression
Negative 332 (34.0%) 126 (12.9%)
4.8 × 10−28 <0.00001Positive 644 (66.0%) 848 (87.1%)
PAM 50 Luminal A
Negative 770 (78.9%) 466 (48.1%)
4.45 × 10−45 <0.00001Positive 206 (21.1%) 502 (51.9%)
PAM 50 Luminal B
Negative 684 (70.1%) 775 (80.1%)
3.68 × 10−7 <0.00001Positive 292 (29.9%) 193 (19.9%)
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Table 1. Cont.
ERCC1 mRNA Expression p-Value * p-Value(Adjusted)
Low High
PAM 50 Her2
Negative 799 (81.9%) 909 (93.9%)
4.39 × 10−16 <0.00001Positive 177 (18.1%) 59 (6.1%)
PAM 50 Basal
Negative 751 (76.9%) 871 (90.0%)
1.089 × 10−14 <0.00001Positive 225 (23.1%) 97 (10.0%)
Integrative Molecular Clusters
Int Clust 1 101 (10.3%) 35 (3.6%)
1.163 × 10−60 <0.00001
Int Clust 2 41 (4.2%) 30 (3.1%)
Int Clust 3 78 (8.0%) 210 (21.6%)
Int Clust 4 144 (14.8%) 187 (19.2%)
Int Clust 5 139 (14.2%) 46 (4.7%)
Int Clust 6 52 (5.3%) 33 (3.4%)
Int Clust 7 74 (7.6%) 112 (11.5%)
Int Clust 8 77 (7.9%) 221 (22.7%)
Int Clust 9 108 (11.1%) 38 (3.9%)
Int Clust 10 162 (16.6%) 62 (6.4%)
Genufu Sub-Types
ER−/Her-2− 104 (21.4%) 44 (8.8%)
7.43 × 10−37 <0.00001ER+/Her-2– (high proliferation) 212 (43.7%) 148 (29.7%)ER+/Her-2– (low proliferation) 85 (17.5%) 281 (56.3%)
Her-2 + 84 (17.3%) 26 (5.2%)
* p values were adjusted according to Benjamini-Hochberg method.
2.2. ERCC1 Transcript and Clinical Outcomes in Patients Receiving Adjuvant Therapy
In the ER+ METABRIC whole cohort, low ERCC1 transcript was associated with higher risk of
death (p = 0.0001) (Figure 1A). In patients who received endocrine therapy, similarly, low ERCC1 was
associated with higher risk of death (p= 0.0001) (Figure S2A). In addition, in the ER+ METABRIC cohort,
we tested 188 DNA repair genes in a multivariate Cox proportional hazards model with backward
stepwise exclusion and identified ERCC1 (among seven other genes) as an independent predictor
for overall survival (OS) (Table S10). As chromosomal instability is a marker of chemo-sensitivity,
we evaluated ERCC1 in ER− METABRIC patients who received chemotherapy. Low ERCC1 mRNA
expression was associated with a decreased risk of death from BC (p= 0.05) (Figure 1B). In a multivariate
Cox regression analysis after controlling for confounders (such as endocrine therapy, chemotherapy
and other validated prognostic factors (ER, PR, HER2, grade, stage, tumour size, TP53 mutation status,
PAM50 molecular subtype and IntClust subclasses)), we confirmed that ERCC1 transcript was an
independent prognostic factor for OS (p = 0.039) and the interaction between ERCC1 and chemotherapy
was also statistically significant (p = 0.020) (Table 2). In ER− tumours, that received no chemotherapy,
ERCC1 did not influence survival (Figure S2B).
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Figure 1. ERCC1, adjuvant chemotherapy and survival. (A) Kaplan Meier curves showing BCSS 
(Breast cancer specific survival) based on ERCC1 mRNA expression in ER+ METABRIC cohort. (B) 
Kaplan Meier curves showing BCSS (Breast cancer specific survival) based on ERCC1 mRNA 
expression in ER− METABRIC cohort. (C) Kaplan Meier curves showing disease specific survival 
based on ERCC1 mRNA expression in ER+ Multicentre Adjuvant (Adj MC) cohort. (D) Kaplan 
Meier curves showing disease specific survival based on ERCC1 mRNA expression in ER− Adj MC 
cohort. (E) Kaplan Meier curves showing disease specific survival based on ERCC1 protein level 
in ER+ Adj MC cohort. (F) Kaplan Meier curves showing disease specific survival based on ERCC1 
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Figure 1. ERCC1, adjuvant chemotherapy and survival. (A) Kaplan Meier curves showing BCSS (Breast
cance spe ifi survival) based on ERCC1 m NA expression in ER+ M TABRIC cohort. (B) Kaplan
Meier curves showing BCSS (Breast cancer specifi survival) based on ERCC1 mRNA expression in ER−
METABRIC cohort. (C) Kaplan Meier curves showi g dis ase sp cific survival b s d on ERCC1 mRNA
expre sion in ER+ Multicentre Adjuvant (Adj MC) cohort. (D) Kaplan Meier curves showing disease
specific survi al based on ERCC1 mRNA expression in ER− Adj MC cohort. (E) Kaplan Meier curves
showing disease specific survival based on ERCC1 protein level in ER+ Adj MC cohort. (F) Kaplan
Meier curves showing disease s ecific survival based on ERCC1 protein level in ER− Adj MC cohort.
Cancers 2019, 11, 1149 6 of 15
Table 2. Multivariate Cox regression analysis for overall survival (OS) at 20 years in the
METABRIC cohort.
Variables HR
95.0% CI p Value
Lower Upper
ERCC1 mRNA expression (+) 1.43 1.02 2.01 0.039 *
ER (+) 0.75 0.38 1.49 0.411
PR (+) 0.91 0.63 1.32 0.624
HER2 overexpression 0.82 0.36 1.85 0.63
TP53 mutation 1.81 1.24 2.63 0.002 *
Tumour Size (continuous) 1.01 1.01 1.02 0.001*
Lymph node (LN) stage
1.2 × 10−6 *Negative 11–3 positive LNs 1.87 1.25 2.79




Intermediate 0.98 0.46 2.09
High 1.2 0.55 2.62
PAM-50 subtypes
0.049 *
PAM-50-LUM A 1 0.97 2.16
PAM-50-LUM B 1.44 0.43 2.16
PAM-50-LUM HER2 0.96 0.5 3.04





IntClust 2 1.28 0.59 2.8
IntClust 3 0.56 0.25 1.24
IntClust 4 0.8 0.4 1.59
IntClust 5 2.47 0.94 6.53
IntClust 6 1.15 0.5 2.64
IntClust 7 1.08 0.49 2.38
IntClust 8 1.03 0.52 2.05
IntClust 9 1.31 0.66 2.58
IntClust 10 0.81 0.38 1.76
Hormone therapy 0.64 0.43 0.96 0.031 *
Chemotherapy 0.93 0.62 1.41 0.741
Interaction term
2.86 1.1 7.42 0.09Hormone therapy * ER (IHC)
Interaction term
2.11 1.23 3.95 0.020 *Chemotherapy * ERCC1
* significant p values.
We then validated in the Multicentre (MC)-Adjuvant cohort of 4640 patients. By using mean as
cut-off, high and low ERCC1 were observed in 49% (1460/2261) and 51% (14602379) of cases, respectively.
ER and HER2 status were available for 3826 and 1727 cases; respectively. About 59% (2268/3826),
41% (1558/3826) and 26% (446/1727) of cases were ER+, ER− and HER2+, respectively (Tables S3 and
S4). Similar to the METABRIC data, in ER+ tumours, low levels of ERCC1 was associated with an
increased distant relapse DRR compared to high levels of ERCC1 [p = 0.007) (Figure 1C). However, in
ER− tumours that received adjuvant chemotherapy, low ERCC1 was associated with a reduced DRR
compared to high ERCC1 (p = 0.001) (Figure 1D). Multivariable Cox regression models confirmed that
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the low ERCC1 transcript is a poor prognostic factor for DRR after controlling with Adjuvant! Online
(AOL) (p = 0.047) and 72-proliferation-gene-signatures (p < 0.0001).
2.3. ERCC1 Protein, Clinicopathological Features and Outcomes
Using median as the cut off (H-score ≥ 130), we observed ERCC1 nuclear protein expression in
439/991 (44.3%) of breast tumours, and 55.7% (552/991) were negative for ERCC1 expression. As shown
in (Table S11), low nuclear ERCC1 level was significantly associated with aggressive phenotypes,
including high grade, no special histological type (NST), ER−, basal-like phenotype and triple negative
tumours, as well as loss of other DNA repair biomarkers (all adjusted p ≤ 0.01). In ER+ tumours,
low ERCC1 protein was linked to poor disease relapse free survival (p = 0.044) (Figure 1E). On the
other hand, in ER− tumours that received chemotherapy, low ERCC1 protein was linked to improved
disease relapse free survival (p = 0.034)) (Figure 1F). Multivariable Cox regression analysis controlling
for chemotherapy, endocrine therapy and other validated prognostic factors (stage, grade, size, ER, PR,
HER2 and BCl2), showed that ERCC1 protein expression was an independent prognostic factor for OS
(p = 0.035) and that the interaction between ERCC1 protein expression and adjuvant chemotherapy
was statistically significant (p = 0.022) (Table S12).
2.4. ERCC1 and Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (pre-operative) is an established approach in locally advanced breast
cancers (LABC). Although current evidence suggests that patients who achieve pCR have a better
long-term clinical outcome [27,28], the development of a predictive biomarker of pCR remains a high
priority. We therefore evaluated ERCC1 transcripts in a multiple centre cohort of 2345 LABC patients
who received neoadjuvant anthracycline based combination (Neo-Adj) AC-chemotherapy (CT) + or − T
with or without Herceptin (+ or – H), including multiple clinical trials sub cohorts (MC-Neo-Adjuvant
cohort). The majority of patients (60%; 1413/2345) had received Neo-Adj AC-CT+T (taxane) whereas
29% (689/2345) and 10% (243/2345) of patients had received Neo-Adj AC-CT alone and AC-CT+T+H;
respectively. About 52% of cases were ER− (1163/2256) whereas 48% (1093/2345) and 24% (518/2163)
were ER+ and HER2+, respectively. Low and high ERCC1 transcript expressions were observed in
48% (1133/2345) and 52% (1212/2345) of cases, respectively. Out of the 2345 patients, 596 (25%) patients
had achieved pCR. Low ERCC1 transcript expression was associated with an increased proportion of
patients achieving pCR (333 (29%) of 1133 patients) compared with high ERCC1 transcript expression
(263 (22%) of 1212 patients; OR (95% CI): 1.50 (1.25–1.81, p < 0.0001).
In ER+ patients, low ERCC1 transcript expression was also associated with a higher proportion of
patients achieving pCR (80 (18%) of 442 patients) compared with high ERCC1 transcript expression
(64 (10%) of 651patients; OR (95% CI): 2.03 (1.42–2.89), p < 0.0001) especially in ER+ patients who
received either Neo-Adj AC-CT alone (21% (29/136) versus 10% (17/166); OR (95% CI): 2.38 (1.24–4.55),
p = 0.008) or Neo-Adj ACT-CT+T (15% (41/276) versus 9% (42/464); OR (95% CI): 1.75 (1.11–2.77),
p = 0.016) (Figure 2A).
In ER− patients who received Neo-Adj AC-CT alone, low ERCC1 transcript expression was also
associated with a higher proportion of patients achieving pCR (74 (33%) of 227 patients) compared with
high ERCC1 transcript expression (37 (23%) of 159 patients (OR (95% CI): 1.59 (1.01–2.53), p = 0.046)
(Figure 2B). We validated this observation in the TOP1 trial cohort of ER-negative tumours where
patients received anthracycline (epirubicin) monotherapy only. Low ERCC1 transcript expression was
associated with an increased proportion of patients achieving pCR (12 (21.4%) of 56 patients) compared
with high ERCC1 transcript expression (4 (6.9%) of 58 patients; OR (95% CI): 3.683 (1.11–12.20),
p = 0.026). Moreover, in the TOP1 cohort, low ERCC1 transcript expression was associated with 58%
lower relapse risk compared to high ERCC1, (HR (95% CI): 0.42 (0.19-0.93); p = 0.033) (Figure 2C). For
additional validation at protein level, we investigated the effect of ERCC1 protein on pCR in a series
of 120 LABC patients who received Neo-Adj AC-CT alone. 19/120 (16%) patients achieved pCR in
this cohort. Low ERCC1 protein expression was associated with an increased proportion of patients
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achieving a pCR (16 (26%) of 62 patients) compared with high ERCC1 protein expression (3 (5%) of
57 patients; OR (95% CI): 6.25 (1.89–22.73, p = 0.002).
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Figure 2. ERCC1 and eoadjuvant chemotherapy. (A) Pathologic l t response (pCR) based on
ERCC1 m NA expression in ER+ tumours (neoadjuv nt anthracycline based (Neo-Adj) MC cohort)
that received neoadjuvant AC or AC+T or AC+T+H chemotherapy. (B) Pathological complete response
(pCR) based on ERCC1 m NA expression in E − tumours (Neo-Adj MC cohort) who received
neoadjuvant AC or AC+T or AC+T+H chemotherapy. (C) Disease free survival based on ERCC1 mRNA
expression in TOP1 cohort patients who received neoadjuvant AC chemotherapy. (D) Disease free
survival based in ER−Neo-Adj MC cohort who received neoadjuvant AC+T chemotherapy. (E) Disease
free survival based in ER+ Neo-Adj MC cohort who received neoadjuvant AC+T chemotherapy.
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On the other hand, in ER− patients who received Neo-Adj ACT+T, high ERCC1 transcript
expression was associated with a higher proportion of patients achieving a pCR (142 (41%) of
349 patients) compared with low ERCC1 transcript expression (110 (34%) of 323 patients; OR (95%
CI): 1.33 (0.97–1.82), p = 0.076) (Figure 2B). In addition, in ER− patients who received pre-operative
Neo-Adj ACT+T, low ERCC1 had higher relapse risk compared to high ERCC1 (HR (95% CI): 1.71
(1.12–2.60); p = 0.013) (Figure 2D). Similarly, in ER+ patients also who received Neo-Adj ACT+T, low
ERCC1 had higher relapse risk compared to high ERCC1 (hazard ratio (HR) (95% CI) = 1.71 (1.03–2.83),
p = 0.039) (Figure 2E).
Taken together, the data provides compelling evidence that ERCC1 has prognostic significance in
ER+ BCs and predict response to chemotherapy in ER− BCs.
3. Discussion
Although the efficacy of DNA damaging chemotherapy (such as anthracyclines) is influenced by
impaired DNA repair capacity, evolving evidence also suggests that mitotic spindle poisons (such as
taxanes) are more effective in low grade chromosomally stable tumours. Therefore the development
of robust DNA repair based biomarkers is highly desirable. ERCC1 is non-catalytic but partners
with XPF endonuclease to form the ERCC1–XPF heterodimer which processes abnormal DNA repair
intermediates generated during NER, double strand breaks (DSB) repair and Interstrand Cross Link
(ICL) repair [29]. Given the key role for ERCC1 in genomic integrity, we hypothesized a role for
ERCC1 in breast cancer pathogenesis and response to therapy. In the current study we show that
ERCC1 transcript expression was independently associated with OS in the METABRIC cohort. In ER+
tumours, low ERCC1 transcript or protein level was associated with increased distant relapse risk
(DRR). In ER− tumours, low ERCC1 transcript or protein level was linked to decreased DRR, especially
in patients who received anthracycline chemotherapy. In LABC patients who received neoadjuvant
anthracycline, low ERCC1 transcript was associated with higher pCR (pathological complete response)
and decreased DRR. However, in patients with ER−tumours who received additional neoadjuvant
taxane, high ERCC1 transcript was associated with a higher pCR and decreased DRR. High ERCC1
transcript was also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane.
Taken together, the data presented here provides comprehensive clinical evidence that ERCC1 is a
predictor of anthracycline resistance and taxane sensitivity in breast cancers. ERCC1 based stratification
could be an attractive strategy in breast cancers.
Studies exploring biomarkers of response to anthracycline therapy have been limited in breast
cancers. Previous smaller studies suggest that Ki67, HER1-3 expression, TOP2A and HER-2 are potential
markers of anthracycline benefit [30]. Ch17CEP, a CIN marker, was also previously shown to predict
benefit from anthracycline adjuvant chemotherapy in a prospective clinical trial [8]. ERCC1 is a critical
factor for CIN. To the best of our knowledge, the data shown here represents the first comprehensive
evidence that ERCC1 status influences potential benefitting from anthracycline chemotherapy. The
role of ERCC1 in breast cancer pathogenesis is emerging. ERCC1 polymorphism may be associated
with increased breast cancer risk [31]. A previous, small study suggested that ERCC1 protein levels
may be low in triple negative breast cancers (TNBCs) [32,33]. In a study of fifty two TNBCs, ERCC1
positivity was associated with shorter progression free survival and poor response to neoadjuvant
chemotherapy [32]. In addition, ERCC1 genetic polymorphism also appeared to associate with
pCR in patients receiving neoadjuvant anthracycline chemotherapy [34]. Gay-Beillile et al. recently
also demonstrated that ERCC1 expression is induced in tumours that receive anthracycline based
neoadjuvant chemotherapy [35]. Previous clinical studies have evaluated the predictive significance of
ERCC1 for response to platinum chemotherapy, in various solid tumours (lung, colorectal, head and
neck, gastric and bladder cancers [36–39]. However, a major limitation has been the use of relatively
non-specific ERCC1 antibodies for immunohistochemistry in previous studies, including in a large lung
cancer clinical trial [40]. In the current study we utilised a recently generated and highly specific mouse
monoclonal antibody (clone 4F9) [41], which further strengthens our clinical data. Our study not only
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concurs with previous studies showing a link between ERCC1 overexpression and chemoresistance
but also provides additional insight suggesting that ERCC1 may also be involved in the emergence of
aggressive breast cancer phenotypes. However, a limitation to our study is that it is predominantly
retrospective. Prospective studies would be required to confirm our findings.
Currently there is no established predictive biomarker of response to taxane therapy. Previous
studies suggest that HER2, Ki67, class III β tubulin expression may influence taxane response [10].
A novel observation in the current study is that ERCC1 was also shown to influence whether taxane
chemotherapy was beneficial. Our data concurs with previous evidence demonstrating taxane benefit
in low grade, chromosomally stable tumours [9,10]. However, further prospective studies would be
required to confirm our initial findings.
Taken together, the data would support further development of ERCC1 as a biomarker of response
to chemotherapy in breast cancer.
4. Patients and Methods
4.1. Study Design and Cohorts
Study design, the patient cohorts which included 11,096 BCs and their demographics are
summarized in the consort flow diagram (Figure 3), also in Supplementary Methods and Tables.
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4.2. Outcome Measurements and Patient Cohorts:
4.2.1. ERCC1 Transcript Expression Analysis
I The association of 188 DNA repair genes and prognosis (overall survival; OS) analysis:
Cohort (1): METABRIC cohort (Molecular Taxonomy of BC International Consortium)
Patient demographics are summarized in Supplementary Table S1. We investigated the association
of 188 DNA repair genes (Table S2) with OS in the METABRIC cohort (METABRIC n = 1980; median
follow-up time in years (MFUT) (inter-quantile range (IQR): 9.1 (5.2–12.9)). Univariate Cox regression
analysis was used in SPSS (Version 20, Chicago, IL, USA) and the Benjamini and Hochberg False
Discovery Rate calculation (BH FDR) was applied to account for multiple comparisons. After definition
of factors that were associated with OS after BH FDR correction, multivariate Cox proportional hazards
models (with backward stepwise exclusion of these factors, using a criterion of p < 0.05 for retention of
factors in the model) were used to identify factors that were independently associated with OS. The
statistical significance of the model was assessed based on the likelihood ratio test. The proportional
hazards assumption was tested using both standard log–log plots and by generating Kaplan–Meier
survival estimate curves, and observing that the curves did not intersect with each other. Hazard
ratios (HRs) for death risk and 95% confidence intervals were calculated from the Cox proportional
hazards analysis.
II The association of distant relapse risk (DRR)) and ERCC1 transcript after receiving systemic
adjuvant therapy (Adj-T):
Cohort (2): Multicentre (MC)-Adjuvant cohort (n = 4640)
The association between ERCC1 mRNA expression and DRR and its relationship with the received
systemic Adj-T were tested in 4640 patients with early stage BC, retrieved from 21 gene expression
databases (see Supplementary Tables S3 and S4). ERCC1 gene expression data of each database were
converted to a common scale (median equal to 0 and standard deviation equal to 1) in order to merge
all of the study data that used the same platform and to create combined cohorts. Then the data
was median centred for each gene, whereby the median of each gene was 0. Databases using the
same platform were merged and the median expression was calculated. The median expression of
ERCC1 transcription for each platform was calculated and values equal to or higher than the median
coded as +1 (overexpression). Values of less than the median were coded 0 or low ERCC1. Distal
relapse free survival follow up data were available for 3171 patients with 967 events (MFUT (IQR):
5.5 (3.0–8.7)). The systemic Adj-T information was available for 2276 patients: 45% of patients were
naïve to systemic Adj-T, whereas 49% had received Adj-endocrine therapy and 27% had received
chemotherapy. Herceptin had been offered to 156 (7%) of HER2 + patients.
III The association between ERCC1 and pathological complete response rate (pCR) analysis after
receiving neoadjuvant anthracycline based combination chemotherapy (Neo-Adj-ACT)
Cohort (3): Multicentre (MC) Neo-Adjuvant cohort (n = 2340)
Demographics summarized in Supplementary Table S5. The association between ERCC1 mRNA
expression and pCR was evaluated in 2340 patients retrieved from 15 gene expression databases that
received pre-operative anthracycline based combination (AC) with (+) or without (−) taxane (T). Out
of 2345 patients, 689 patients (29%) has received Neo-Adjuvant anthracycline based combination
chemotherapy (Neo-Adj-ACT) alone; 1413 patients (60%) received Neo-Adj-ACT with Taxane (ACT +
T) and 243 patients received Neo-Adj-ACT + T + Herceptin (ACT + T + H).
Cohort (4): Neoadjuvant TOP trial cohort (NCT00162812), in which patients with oestrogen receptor
(ER)-negative tumours were treated with anthracycline (epirubicin) monotherapy. Demographics
summarized in Supplementary Table S6.
4.2.2. Protein Expression Association Analysis
Immunohistochemical evaluation of ERCC1 protein expression was performed in three cohorts of
patients who treated at a single centre (Nottingham University Hospital (NUH)). We utilised a recently
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characterised highly specific anti-ERCC1 mouse monoclonal antibody (clone 4F9, Dako Ltd., Cheshire,
UK) [18]. We confirmed the specificity of clone 4F9, using Western Blots in breast cancer (SKBR3, T47D
and MDA-MB-231) and ovarian cancer (A2780 and A2780cis) cell lines (Supplementary Figure S1A).
Tissue culture and Western blot analyses is described in Supplementary Methods.
4.3. Adjuvant Setting
Cohort (5): NUH- early stage breast cancer (NUH-ESBC): The study was performed in a well
characterised consecutive series of 1650 patients with primary invasive breast carcinomas who were
diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma
series [42] (Nottingham historical early stage cohort (NUH-ESBC); MFUT (IQR): 13.4 (10.3–16.42)).
Demographics are summarized in Supplementary Table S7. Supplementary Methods provide a detailed
description on Tissue Microarrays (TMAs) and immunohistochemistry (IHC) evaluations (Table S8).
The association between the ERCC1 protein expression with clinicopathological parameters and DRR
were analysed in this cohort.
Cohort (6): (Nottingham ER-negative series). A series of 252 ER negative invasive breast
carcinomas diagnosed and managed at the Nottingham University Hospitals (NUH) Trust between
1999 and 2007. All patients were primarily treated with surgery, followed by adjuvant radiotherapy
and anthracycline based combination chemotherapy [43]. Demographics are shown in Supplementary
Table S9.
4.4. Neo-Adjuvant Setting
Cohort (7): Nottingham anthracycline based neo-adjuvant chemotherapy cohort (Nottingham
AC-NACT; n = 120) consisting of pre-chemotherapy core biopsies from 120 female patients with
locally-advanced primary BC treated with neo-adjuvant (Neo-Adj) anthracycline-based combination
chemotherapy (AC-CT) (Neo-Adj-AC-CT) treated at NUH between 1996 and 2012 [42].
All patients completed written informed consented, as per hospital standard of care, for excess
tumour tissue to be used in research. The study was approved by the Institutional Review Board
or Independent Ethics Committee and the Hospital Research and Innovations Department at all
participating sites. Tumour Marker Prognostic Studies (REMARK) criteria, as recommended by
McShane et al. [44] were followed throughout this study.
4.5. Power Analysis
A retrospective power analysis was conducted to determine the confidence in the calculated
hazard ratio and associated p value for 10 year survival and to ascertain how applicable the result
would be to a global population. Power of study was determined using PASS (NCSS, version 13, USA).
4.6. Statistical Analysis
Statistical analyses were performed using STATISTICA (Stat Soft Ltd., Tulsa, OK, USA) and SPSS
(version 17, Chicago, IL, USA) by the authors who were blinded to the clinical data. Where appropriate,
Pearson’s chi-squared, student’s t-test and ANOVA tests were used. Positivity for ERCC1 protein
both pre- and post-chemotherapy was calculated and compared using McNemar’s test. Cumulative
survival probabilities and 10-year BCSS and DFS were estimated using the univariate Cox proportional
hazards models and the Kaplan–Meier plot method where appropriate, and differences between
survival rates were tested for significance using the log-rank test. Multivariable analysis for survival
was performed using the Cox proportional hazard model. The proportional hazards assumption was
tested using standard log–log plots. Hazard ratios (HR) and 95% confidence intervals (95% CI) were
estimated for each variable. All tests were two-sided with a 95% CI, and a p value < 0.05 was considered
to be indicative of statistical significance. The interaction between ERCC1 and chemotherapy was
tested in the Cox proportional hazard model. For multiple comparisons, p values were adjusted
according to Benjamini–Hochberg method [45]. Tumor Marker Prognostic Studies (REMARK) criteria,
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recommended by McShane et al. [46], were followed throughout this study. Ethical approval was
obtained from the Nottingham Research Ethics Committee (C202313).
5. Conclusions
ERCC1 is non-catalytic but partners with XPF endonuclease to form the ERCC1–XPF heterodimer
which processes abnormal DNA repair intermediates generated during NER, DSB repair and ICL repair.
We provide the first comprehensive clinical evidence that ERCC1 is a key predictor of chemotherapy
response in patients with breast cancer who receive adjuvant or neoadjuvant chemotherapy. Importantly,
the clinical study suggests that ERCC1 based stratification is feasible in BC patients who receive
anthracycline and/or taxane chemotherapy.
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Neo-Adjuvant cohort (n= 2345), Table S6: Demographics in TOP trial cohort, Table S7: Clinicopathological
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series including interaction terms.
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